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Results in clinical trials 
Pesonen, S., et al. developed Ad5-D24-RGD-GMCSF, 
the first armed integrin targeted adenovirus used in 
humans. Summarized results can be found in the table 
below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Results obtained in human clinical trial. Data taken from  
(Pesonen et al., 2012). 
Adenovirus gene therapy 
Adenoviruses (Ad) are DNA-containing non-enveloped viruses. The ability of adenovirus to be grown to a 
high titer and to engage in high-level heterologous gene expression has made human adenovirus 
popular gene therapy vectors.  Below, a number of developments  in the subject of the review are 
summarized.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. A summarized view of the aspects in which adenoviral gene therapy for osteosarcoma has evolved. 
Introduction 
Gene-based therapy has emerged as a potentially powerful therapeutic platform, and in 64.3% of cases, 
indications addressed by this tool are for cancer diseases. Osteosarcoma is one of the most common, 
nonhematologic primary bone tumours. Most patients have no specific clinical symptoms, however, when 
present, the most frequent symptom is pain, usually present several weeks or months prior to diagnosis. The 
most frequent presenting clinical sign is a firm and tender mass, often brought to attention to by a minor 
trauma. Next to the tumour in the musculoskeletal system, lung metastasis eventually causes the patient’s 
death in the vast majority of cases which develop metastatic disease. One of the most widely used vectors in 
cancer gene therapy (23.2%), is the adenoviral vector, which offers advantages such as growing to high titers 
and capability of infecting a variety of cells in different tissues. This review is focused on the aspects that 
gene therapy using adenovirus has evolved so far, chiefly directed to the treatment of osteosarcoma.  
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Fig 1. Adenoviral particle and its genome 
organisation. Extracted from <genetherapynet.com> 
Gene therapy 
Ad Vector 
Modification 
Obstacles Target 
Clinical 
stage 
Mechanisms Results 
Trial 
organism 
Tumour 
suppressor gene 
dysfunction 
pRb and p16INK4A  
Less effective in 
the presence of 
functional pRb 
in cancer cells.  
pRb null tumour 
cells 
Preclinical Restoration of pRb. 
Supress 
tumorigenicity 
Nude mice 
p53 (p53VP∆30) 
No clearance of 
the tumour. 
Transformed cells Preclinical 
Accumulation of 
p53VP∆30, 
regardless of 
endogenous p53 and 
Mdm2 status.  
Induction apoptosis Nude mice 
Transductional 
targeting 
Ad-D24-RGD and 
Ad-RGD-D24-
GMCSF 
Side effects αvβ integrins  Clinical trial 
Activation of 
dendritic cells. 
Replication only in 
tumour cells 
Human 
Protein targeting Ad-Rybp 
Resistance in 
some cell lines, 
combination 
with other 
agents 
required. 
Transformed cells Preclinical 
Introduced into 
normal cells, Rybp 
remains in the 
cytoplasm, whereas 
it remains in the 
nucleus of 
transformed cells. 
Induction apoptosis Cell culture 
Viriotherapy 
Telomelysin 
No clearance of 
the tumour. 
Cells expressing 
hTERT 
Preclinical Unknown 
Tumour-targeted 
oncolysis. 
Nude mice 
OAT 
Resistance, 
large quantities 
Cells expressing 
TERT 
Preclinical Unknown 
Apoptosis selectively 
to tumour cells. 
Nude mice 
CRAd5.TRAIL/siEag
1 
No clearance of 
the tumour 
Eag1-positive 
cancer cells  
Preclinical 
Silence Eag1 
expression and 
increase sensitivity 
of OS cells to 
CRAd5.TRAIL-
mediated apoptosis. 
Tumour growth 
inhibition; Apoptosis 
in osteosarcoma 
xenografts. 
Nude mice 
Adenoviruses used in humans 
Side effects Fatigue, fever and injection site pain. 
Virus 
presence in 
the 
circulation 
77% of evaluable patients showed virus 
in circulation for at least 2 weeks.  
Tumour-
specific 
immune 
response 
Only one patient showed induction of 
surviving specific T-cell 1 month after 
treatment with Ad5-RGD-D24-GMCSF 
and they were detectable also two 
months after virus injection.  
Antitumour 
responses 
and 
survival 
In 3/6 evaluable patients, disease 
previously progressing stabilized after a 
single treatment with  Ad5-RGD-D24-
GMCSF. In addition, 2/3 patients had 
stabilization or reduction in tumour 
marker levels. All patients treated with 
Ad5-D24-RGD showed disease 
progression in radiological analysis.  
Biosafety 
concerns 
Activation of 
innate immunity  
Vector related 
toxicity 
Rapid clearance 
from systemic 
circulation 
Conclusions 
 Prolonging the survival of patients is a goal trying to be reached. 
 A wide knowledge in molecular basis of osteosarcoma is essential to find new targets to reach 
those malignant tumour cells. 
 An appealing aspect for future studies is the development of studies in humans. Further 
optimization of the treatment protocol is required, focusing on repeated injections, combining with 
other therapies and to lower tumour load patients, whose tumours might be less immune suppressive. 
